GE HealthCare has introduced two AI-assisted features, AutoAS and Lung Guidance, for its Vscan Air handheld ultrasound system.
Both programmes have obtained 510(k) clearance from the US Food and Drug Administration (FDA), as well as CE mark certification.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The additions assist clinicians in evaluating patients with respiratory and cardiac symptoms at the point of care, particularly when specialist imaging access is constrained.
AutoAS offers an automated visual estimation of moderate-to-severe aortic stenosis by assessing standard 2D echocardiographic views obtained on the Vscan Air SL.
The programme analyses at least two compatible angles, choosing from the apical five-chamber (AP5), parasternal long-axis (PLAX), or parasternal short-axis at the aortic valve (PSAX-AV).
Alongside the assessment, it generates a score reflecting algorithmic confidence. Validated against a reference panel of expert cardiologists, the software is designed to curb the diagnostic variability associated with visual evaluation alone.
For pulmonary examinations, Lung Guidance offers real-time scanning directions across the standard eight-zone lung protocol.
The software detects key anatomical landmarks, including A-lines, the abdomen, the diaphragm, the pleural line, and rib shadows.
An AutoCapture mechanism records clips automatically once image quality metrics are satisfied, whilst a secondary feature enables clinicians to preserve the highest quality image from each view.
The system also supports B-line identification, scoring, and clinical reporting. In descriptive validation tests, non-expert users secured diagnostic-quality lung scans in 95.2% of evaluations, compared to 96.8% achieved by expert operators.
GE HealthCare ultrasound solutions, advanced imaging solutions CEO Karley Yoder said: “Clinicians at the point of care are often working with limited time and incomplete information, and a symptom like shortness of breath rarely announces if it’s coming from the heart, the lungs, or both.
“Lung Guidance and AutoAS are designed to shorten the distance between the initial physical assessment and a clear next step, putting AI-enabled tools in the hands of the clinician who is already with the patient.”
The software joins GE HealthCare’s broader point-of-care line-up, which includes the LOGIQ e family, Venue family systems, and Vscan Air.
The updates are being released through Vscan Air Innovation Packages in select countries and the US, with current eligible licence holders scheduled to receive access by late November 2026.
Last month, GE HealthCare reported Q3 revenues of $5.5bn, with notable year-over-year growth in its pharmaceutical diagnostics segment, prompting the company to raise its 2026 outlook.
